Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate. Chiuppesi et al . demonstrate the use of a synthetic poxvirus-based platform to rapidly generate multi-antigenic vaccine candidates expressing spike and nucleocapsid antigens of SARS-CoV-2. Immunization of mice stimulates potent antigen-specific humoral and cellular immune responses, including neutralizing antibodies.
【저자키워드】 SARS-CoV-2, viral infection, Live attenuated vaccines, 【초록키워드】 Vaccine, Neutralizing antibodies, Cancer, Infectious disease, SARS-CoV-2 vaccine, Antigen, global pandemic, DNA, protective immunity, mice, vector, vaccine candidate, poxvirus, vaccine platform, platform, nucleocapsid antigen, SARS-CoV-2 spike, Coronavirus-2, humoral, cellular immune responses, vaccinia, immunodominant, nucleocapsid antigens, immunized, robust, develop, caused, generate, unique, expressing, stimulate, implicated, 【제목키워드】 SARS-CoV-2 vaccine, poxvirus, development, platform,